About the report
The Commission released its Fourth Australian report on antimicrobial use and resistance in human health (AURA 2021) in August 2021 to continue to raise awareness of trends in antimicrobial resistance (AMR) in the hospital and community settings, and priorities for control and prevention of AMR and improvement of antimicrobial use (AU). This Report provides a valuable source of data on which to base the development of targeted strategies to prevent and contain AMR; to support improved antimicrobial prescribing and use; and to improve the safety and quality of healthcare to patients.
This report includes AMR and AU data from across Australia and builds on the analyses presented in the three previous national AURA Reports (AURA 2016, AURA 2017, and AURA 2019).
AURA 2021 includes analyses of AMR and AU data predominantly collected in 2018 and 2019; with 2020 data from the National Alert System for Critical Antimicrobial Resistances (CARAlert), and 2020 data on dispensing of antibiotics under the Pharmaceutical Benefits Scheme (PBS) in the context of the COVID-19 pandemic.
The AURA data and the analyses of clinical impact included in AURA 2021 continue to support states, territories, the Australian Government, the private sector, and clinicians working across those organisations to take action to prevent and control AMR and improve antimicrobial use; inform clinical practice; and, importantly improve patient safety.
The AURA Surveillance System also supports implementation of Australia’s National Antimicrobial Resistance Strategy – 2020 and Beyond (the National AMR Strategy).
AURA Surveillance System data also supports implementation of the National Quality and Safety Health Service Preventing and Controlling Infections Standard by informing the Actions of the Standard and the assessment of compliance.
The AURA Surveillance System demonstrates Australia’s continuing commitment to addressing the challenges of AMR, guiding action to preserve the effectiveness of antimicrobial medicines through responsive health policy, and influencing clinical practice change, where needed.
A number of related reports and resources are available, including a Highlights Report and a Consumer Summary.